Response of vascular pigment epithelium detachment due to age‐related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study

Purpose To assess the effects of monthly intravitreal ranibizumab injections in patients with vascularized pigment epithelium detachment (vPED) secondary to age‐related macular degeneration (AMD). Methods A total of 40 patients were prospectively observed and treated monthly with 0.5 mg ranibizumab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta ophthalmologica (Oxford, England) England), 2017-11, Vol.95 (7), p.683-689
Hauptverfasser:	Clemens, Christoph R., Wolf, Armin, Alten, Florian, Milojcic, Carolin, Heiduschka, Peter, Eter, Nicole
Format:	Artikel
Sprache:	eng
Schlagworte:	Acuity Age Aged age‐related macular degeneration Angiogenesis Inhibitors - administration & dosage Angiography antivascular endothelial growth factor confocal scanning laser ophthalmoscopy Drug Administration Schedule Epithelium Female Fluorescein Fluorescein Angiography Follow-Up Studies Fundus Oculi Group dynamics Humans I.R. radiation Immunotherapy Infrared imagery Intravitreal Injections Lesions Macular degeneration Male Medical imaging Monoclonal antibodies Optical Coherence Tomography Physical characteristics pigment epithelium detachment Prospective Studies ranibizumab Ranibizumab - administration & dosage Retina Retinal Detachment - diagnosis Retinal Detachment - drug therapy Retinal Detachment - etiology Retinal pigment epithelium Retinal Pigment Epithelium - pathology retinal pigment epithelium tear Risk factors spectral‐domain optical coherence tomography Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascularization Visual Acuity Wet Macular Degeneration - complications Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!